Enara Bio

About Enara Bio

Enara Bio is a biotechnology company focused on advancing cancer immunotherapy by targeting unconventional antigens, specifically 'Dark Antigens,' to develop therapies that provide lasting benefits for broad cancer patient populations. Their mission is to enable people to live free from the shadow of cancer using their innovative EDAPT platform.

Products & Services

EDAPT Platform:An innovative technology platform integrating bioinformatics, immunopeptidomics, target validation, and immunology to discover novel cancer-specific targets called Dark Antigens for immunotherapy.

TCR-based Immunotherapies:First-in-class therapies targeting novel Dark Antigens to treat cancer.

Specialties

Cancer Immunotherapy Dark Antigens T-cell Biology TCR-based Therapies Immunopeptidomics Bioinformatics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 32500000 MR: - FA: 32.5 million FAN: 32500000	D: 2024-10-03 FD: 2024-10-03	6 investors

Series B Latest

2024-10-03

$32.5M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Kevin Pojasek

President and Chief Executive Officer

D

David Watson

Chief Operating Officer

S

Sophie Papa

Chief Medical Officer and Head of Translational Science

J

Joseph Dukes

Chief Scientific Officer

S

Stacey Davis

Chief Business Officer and Chief Financial Officer

R

Robert Ang

Chair

View 15 more team members with Pro

Unlock Full Team Directory

Recent News

Enara Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised